Prelude Capital Management’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $348K | Sell |
5,543
-10,818
| -66% | -$753K | 0.03% | 649 |
|
|
2025
Q4 | $1.09M | Buy |
16,361
+13,157
| +411% | +$851K | 0.08% | 280 |
|
|
2025
Q3 | $216K | Buy |
+3,204
| New | +$254K | 0.02% | 906 |
|
|
2025
Q2 | – | Sell |
-3,823
| Closed | -$261K | – | 1091 |
|
|
2025
Q1 | $261K | Buy |
+3,823
| New | +$312K | 0.02% | 771 |
|
|
2024
Q3 | – | Sell |
-15,189
| Closed | -$1.72M | – | 1348 |
|
|
2024
Q2 | $1.72M | Sell |
15,189
-1,001
| -6% | -$127K | 0.12% | 219 |
|
|
2024
Q1 | $2.25M | Buy |
+16,190
| New | +$2.04M | 0.12% | 212 |
|
|
2023
Q4 | – | Sell |
-17,664
| Closed | -$1.65M | – | 1174 |
|
|
2023
Q3 | $1.65M | Buy |
+17,664
| New | +$1.99M | 0.11% | 221 |
|
|
2023
Q2 | – | Sell |
-3,085
| Closed | -$358K | – | 1190 |
|
|
2023
Q1 | $358K | Sell |
3,085
-9,787
| -76% | -$1.1M | 0.02% | 581 |
|
|
2022
Q4 | $1.46M | Sell |
12,872
-2,172
| -14% | -$238K | 0.08% | 284 |
|
|
2022
Q3 | $1.21M | Sell |
15,044
-375
| -2% | -$31.8K | 0.04% | 363 |
|
|
2022
Q2 | $1.15M | Sell |
15,419
-5,753
| -27% | -$525K | 0.03% | 477 |
|
|
2022
Q1 | $2.71M | Buy |
21,172
+15,012
| +244% | +$1.64M | 0.08% | 247 |
|
|
2021
Q4 | $827K | Buy |
6,160
+12
| +0.2% | +$1.72K | 0.02% | 709 |
|
|
2021
Q3 | $841K | Buy |
+6,148
| New | +$775K | 0.02% | 641 |
|
|
2021
Q1 | – | Sell |
-3,772
| Closed | -$349K | – | 1614 |
|
|
2020
Q4 | $349K | Sell |
3,772
-3,396
| -47% | -$303K | 0.01% | 852 |
|
|
2020
Q3 | $739K | Buy |
7,168
+1,924
| +37% | +$201K | 0.04% | 338 |
|
|
2020
Q2 | $531K | Buy |
+5,244
| New | +$469K | 0.03% | 460 |
|
|
2019
Q2 | – | Sell |
-31,840
| Closed | -$1M | – | 1771 |
|
|
2019
Q1 | $948K | Sell |
31,840
-11,532
| -27% | -$405K | 0.05% | 343 |
|
|
2018
Q4 | $1.3M | Buy |
43,372
+10,948
| +34% | +$347K | 0.09% | 265 |
|
|
2018
Q3 | $1.16M | Sell |
32,424
-11,080
| -25% | -$344K | 0.07% | 339 |
|
|
2018
Q2 | $1.03M | Sell |
43,504
-4,276
| -9% | -$90.7K | 0.07% | 320 |
|
|
2018
Q1 | $886K | Buy |
+47,780
| New | +$707K | 0.06% | 307 |
|
|
2016
Q2 | – | Sell |
-5,684
| Closed | -$97K | – | 1607 |
|
|
2016
Q1 | $97K | Buy |
5,684
+5,656
| +20,200% | +$94.5K | 0.01% | 771 |
|
|
2015
Q4 | $1K | Buy |
+28
| New | +$583 | ﹤0.01% | 1414 |
|
|
2015
Q1 | – | Sell |
-2,800
| Closed | -$39K | – | 1988 |
|
|
2014
Q4 | $39K | Buy |
+2,800
| New | +$34.3K | 0.01% | 1395 |
|
Other funds holding DXCM
VCM
VPM
Prelude Capital Management's DXCM Position: Q1 2026 in Review
Prelude Capital Management reduced its DexCom (DXCM) stake by 66% in Q1 2026, selling an estimated $753K and leaving 5,543 shares worth $348K. The position accounts for 0.03% of the portfolio, ranked #649.
Prelude Capital Management first reported a position in DXCM in Q4 2014 and has held it in 25 quarters since. The position peaked at $2.71M in Q1 2022. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Prelude Capital Management held 5,543 shares of DexCom worth $348K as of Q1 2026.
- Prelude Capital Management sold 10,818 DexCom shares in Q1 2026, an estimated $753K.
- DexCom made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #649 holding.
- Prelude Capital Management first reported a position in DexCom in Q4 2014 and has held it in 25 quarters since.
- Prelude Capital Management's DexCom position peaked at $2.71M in Q1 2022.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.